Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Sponsor : Jazz Pharmaceuticals
Deal Size : $880.0 million
Deal Type : Acquisition
Jazz Pharmaceuticals Enters Agreement with Redx to Acquire KRAS Inhibitor Program
Details : Through the acquisition, Jazz Pharmaceuticals will have access to Redx Pharma KRAS inhibitor program for all clinical development, regulatory, manufacturing, and commercialization activities.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $10.0 million
July 02, 2024
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Sponsor : Jazz Pharmaceuticals
Deal Size : $880.0 million
Deal Type : Acquisition
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Redx Provides Progress Update on RXC007 Clinical Programm
Details : RXC007 is an oral, selective Rho Associated Coiled-Coil Containing Protein Kinase 2 (ROCK2) inhibitor which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 02, 2023
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RXC007
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jounce Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Termination of Proposed Business Combination of Jounce Therapeutics, Inc. and Redx Pharma plc
Details : Under the termination, Jounce Therapeutics will not merge with Redx. The business combination was supposed to aim the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic ...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
March 04, 2023
Lead Product(s) : RXC007
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jounce Therapeutics
Deal Size : Undisclosed
Deal Type : Termination
Lead Product(s) : RXC007
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Jounce Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Redx and Jounce Announce Recommended Business Combination
Details : Through the business combination, the combined group's priority will be the development of RXC007, a next-generation selective ROCK2 inhibitor, which is currently being assessed in a Phase 2a study in idiopathic pulmonary fibrosis (IPF).
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
February 23, 2023
Lead Product(s) : RXC007
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Jounce Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Simbec-Orion
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 06, 2022
Lead Product(s) : RXC007
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Simbec-Orion
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : A second arm of the trial, evaluating RXC004 in combination with the anti-PD-1 antibody nivolumab in patients with MSS mCRC, is expected to commence in the first half of 2022 once a recommended dose has been established in the ongoing Phase 1 dose escala...
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 15, 2021
Lead Product(s) : RXC007
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Study Phase : Phase I
Sponsor : Simbec Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 18, 2021
Lead Product(s) : RXC007
Therapeutic Area : Trauma (Emergency, Injury, Surgery)
Highest Development Status : Phase I
Sponsor : Simbec Research
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RXC004
Therapeutic Area : Oncology
Study Phase : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
June 01, 2021
Lead Product(s) : RXC004
Therapeutic Area : Oncology
Highest Development Status : Phase II
Sponsor : Merck & Co
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 28, 2021
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Discovery
Sponsor : Jazz Pharmaceuticals
Deal Size : $420.0 million
Deal Type : Collaboration
Details : Under the terms of the collaboration agreement, Redx will be responsible for research and preclinical development activities up to Investigational New Drug (IND) submission.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : $10.0 million
September 09, 2020
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Discovery
Sponsor : Jazz Pharmaceuticals
Deal Size : $420.0 million
Deal Type : Collaboration